Published On: Wed, Oct 19th, 2016

Shire Plc (LON:SHP) Receives Overweight Rating From Jefferies Analysts


Shire Plc (LON:SHP) had its stock rating reiterated as ‘Overweight’ in a report released by analysts at Jefferies.

Jefferies today set a target price of 6300 on the company’s stock. According to the analyst this now indicates there is a potential increase of 22.43% from Shire Plc’s current price of 5146.

LON:SHP


Over the last twelve months Shire Plc’s stock price has increased by 11.78% from 4603.72 to 5146.

There are currently 682,799,000 shares in issue with a current share value of 5146 giving Shire Plc a market capitalisation of 35.14B GBp .

Shire Plc (LON:SHP) has a 50 day moving average of 5022.47 and a 200 day moving average of 4625.73. The 52 week high for the share price is 5377 while the 52 week low for the stock is 2707.19.

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).